Chiropractic Management of Migraine Headache

Chiropractic Management of Migraine Headache

The upcoming holiday season will bring changes in diet, sleep, weather, and stress, each of which is a potential trigger for migraine headaches. This month’s clinical review provides the current best-practice management of this common and debilitating problem that you’re sure to see.

Introduction & Etiology

“Migraine” is a complex, chronic neurologic disorder characterized by recurrent moderate to severe headaches. The diagnosis of migraine is subdivided into “migraine without aura” (formerly common migraine), and “migraine with aura” (formerly classic migraine). (1) “Aura” is the collection of autonomic nervous system symptoms that occur immediately prior to the headache. (2) Aura symptoms may include visual disturbances, extremity paresthesia, nausea, vomiting, and hypersensitivity to light or sound.

Early explanations for the genesis of migraine focused on cerebrovascular vasoconstriction with subsequent vasodilation. (3) Migraine is now recognized as a more complex series of neurologic and vascular events wherein vasodilation may or may not be present. (4-8) Evidence suggests that a migraineur’s brain is hyper-excitable and uniquely predisposed to migraine headaches in much the same way that an epileptic is susceptible to seizures. (8,9) Migraineurs also demonstrate changes in the performance of functional tasks, suggesting early motor control deterioration. (87)

Worldwide, the lifetime prevalence of migraine is 14%. (10) The one-year prevalence of migraine is 10% and shows little variance worldwide. (11) Over 30 million Americans suffer at least one migraine headache each year. (12) The condition affects 18- 21% of females and 6-10 % of males and is the leading cause of “severe” headaches. (12,88) One in six American women suffers from migraine headaches. (13) Migraine headaches cause more work-related disability and lost productivity than any other common type of headache. (121) Over 80% of migraineurs miss work as a result of their headaches, with an average of 4-6 absences per year. (14) The economic cost of migraine due to lost workdays is estimated at over 13 billion dollars per year in the United States. 

The incidence of migraine without aura peaks in boys at age 10 and in girls age 17. (13) Interestingly, the incidence of migraine with aura peaks almost 5 years earlier for both sexes. (13) Before puberty, migraine is more common in boys. (15) At puberty, this ratio flips, and adult females are three times more likely than their male counterparts to experience migraine. (15) Migraine prevalence peaks in the third decade, and attacks generally decrease in severity and frequency after age 40. (15,81) The onset of a new migraine headache after age 50 is rare. (15) 

Various risk factors have been identified for the development of this disorder. Migraine headaches demonstrate a strong genetic component. Having a first-degree relative with migraine increases one’s risk fourfold. (16) If one parent has migraines, the child has a 50% risk of developing the disorder. If both parents are affected, the risk climbs to 75%. (17) Overweight patients are more susceptible to migraine. (18,119) Low cardiovascular fitness increase risk. (102) Vascular risk factors include hypertension, hypercholesterolemia, impaired insulin sensitivity, coronary artery disease, and a history of stroke. (18)

Medication overuse is one of the more important risk factors for migraine progression. (19) Migraines tend to become “chronic” following overuse of acetaminophen, naproxen, aspirin, opiates, barbiturates, and triptans. (19) One study demonstrated that NSAIDs were beneficial when used less than 10 days a month but induced migraine progression to a chronic state when used at a higher frequency. (19) Hypocalcemia and vitamin D deficiency are associated with an increased risk of migraine attack. (97)

The (hyper-excitable) migraineur brain is susceptible to various “triggers.” Migraines develop when the number of triggers exceeds a critical threshold for a given patient. Known triggers include: stress, smoking, strong odors (i.e. perfumes), bright or flickering lights, fluorescent lighting, excessive or insufficient sleep, head trauma, weather changes, high humidity, motion sickness, cold stimulus (i.e. ice cream headaches), lack of activity/exercise, dehydration, hunger or fasting, and hormonal changes, including menstruation, and ovulation. (20,99) Upper cervical tension or the presence of a cervicogenic headache may be a trigger for a migraine. (59,65)

Certain medications, including estrogen, oral contraceptives, vasodilators, nitroglycerine, histamines, reserpine, hydralazine, and ranitidine are known triggers. (21) Food triggers are inconsistent among migraineurs, but the following foods are regularly implicated: alcohol (especially beer or red wine with tannins), excessive caffeine, artificial sweeteners, MSG, soy sauce, citrus foods, papayas, avocados, red plums, overripe bananas, dried fruits with sulfites (figs, raisins, etc.), sour cream, buttermilk, nuts, peanut butter, sourdough bread, aged meats and cheeses, processed meats, and anything fermented, pickled or marinated. (22,23) It is unclear whether chocolate is a trigger to migraine, or a craving brought on at the onset of an attack. (22) 

Download this list of potential migraine triggers for your patients:

Clinical Presentation

Migraine progresses through various symptomatic stages, including prodrome, aura, attack, and postdrome. The features of migraine headache, including prodrome, vary widely but tend to be consistent for any given individual. (8)

Approximately 60% of sufferers report prodromal symptoms in the hours to days before headache onset. (8) These symptoms include lethargy, yawning, food cravings, mood changes, excessive thirst, fluid retention, constipation, diarrhea, and hypersensitivity to light, sound, or odors. (8) 

About 20-33 percent of migraine sufferers experience auras during or before the headache attack. (17,26) Aura symptoms develop slowly, over 5-20 minutes and can last up to an hour. Symptoms are most commonly visual but may also include a combination of sensory and motor components. The most common visual symptom is a band of absent vision with an irregular shimmering border (scintillating scotoma). (8) Various other visual field defects, including tunnel vision, have been reported. Paresthesias are the next most common aura, occurring in 40% of cases. (28) Paresthesias may be followed by numbness that often begins in the hand and progresses up the arm, to the face, lips, and tongue. Less than one in five migraine sufferers experience motor symptoms, including a sense of heaviness in their limbs or speech and language disturbances. (28) Motor and sensory complaints, including paresthesia and numbness rarely occur in isolation. (28) Visual disturbances that occur in isolation are called “ophthalmic” migraine, aka “retinal,” or “ocular.”Ophthalmic migraines generally produce a lateral field deficit and are more common in children. (8) The slow development of auras (5-20 minutes) is a helpful characteristic in distinguishing migraine from other cerebrovascular pathology (Stroke, TIA). (28)  

During the attack phase, patients will typically complain of a unilateral, moderate to severe, throbbing or pulsating headache. The pain may be felt anywhere in the head and neck but is most common in the frontal, temporal and ocular areas. Headache pain develops over a period of one to two hours and can last between 4 and 72 hours. Patients often report hypersensitivity to sound or light and retreat to quiet, dark places. Hypersensitivity to smell is reported in nearly half of migraine patients. (103) Eighty percent of migraine sufferers experience nausea. (30-32) Vomiting occurs in 1/3-1/2 of patients. (30-32) Seventy-five percent of migraine sufferers report some type of associated neck discomfort. (32)

Postdromal symptoms occur in the hours following a migraine and generally include fatigue, irritability, euphoria, myalgia, food insensitivity, or cravings. (22) Although not necessarily a postdromal symptom, migraine patients are two times more likely to suffer from chronic dry eye disease. (94)

According to the International Headaches Society, the diagnosis of migraine requires at least five episodic headaches, each lasting four to 72 hours associated with nausea/ vomiting or photophobia/ phonophobia and at least of two of the following characteristics: moderate to severe intensity, unilateral presence, pulsating quality, and aggravated by physical activity. (34) Although the aforementioned criteria “define” migraine, it is important to note that not all patients meet these criteria. Forty-one percent of migraine patients report bilateral pain and 50% report “non-pulsating” pain. (30-32) 

Researchers have identified the presence of nausea, disability, and photophobia as the most significant predictors for migraine. (36) A self-administered screening tool called ID migraine ® poses the following questions: 

    1. Are you nauseated or sick to your stomach when you have a headache? 

    2. Has the headache limited your activities for a day or more in the last three months? 

    3. Does light bother you a lot more when you have a headache?

An affirmative response on 2 of 3 questions yields high sensitivity (81%) and specificity (75%). (36,96) 

Clinicians should be alert to “red flags” that suggest a more threatening diagnosis, including: headaches that are becoming progressively worse over time, sudden onset, severe headaches, new or unfamiliar headache, headache following a recent head injury, unexplained weight loss, impaired consciousness, presence of fever, significant neck stiffness, rash, nuchal rigidity, vertigo, diplopia, drop attacks, difficulty speaking, difficulty swallowing, difficulty walking, and nystagmus. 

The American Headache Society endorses the acronym “SNOOP” to identify worrisome headache red flags. (37-38)

  • Systemic symptoms: fever, weight loss, or the presence of systemic risk factors (i.e. cancer, HIV). 
  • Neurologic signs: confusion, impaired alertness, or consciousness.
  • Onset: sudden or abrupt headaches that develop and peak very quickly.
  • Older: new headaches in patients over 50 (Giant cell arteritis, aka temporal arteritis)
  • Previous headache history: any new headache that deviates significantly from a prior pattern of frequency, severity, and clinical features. 

The diagnosis of migraine is based on the patient’s history. (39) A thorough physical and neurologic assessment is required to exclude a more threatening diagnosis; however, the results are normal in most migraine patients. Measurement of vital signs may demonstrate transient irregularities during a migraine attack, including tachycardia, bradycardia, hypertension, or hypotension. Physical exam may demonstrate a mild Horner’s syndrome (ptosis, miosis) on the same side as a headache. (8) The presence of papilledema warrants consultation. Clinicians should palpate the temporal artery in those over age 50 to exclude giant cell arteritis. Migraine patients often demonstrate limited upper cervical and global cervical range of motion. (93)

Clinicians should be cognizant of potential concurrent cardiovascular and cerebrovascular issues when assessing migraine patients. The presence of migraine increases one’s risk of cardiovascular disease (stroke and myocardial infarction) by approximately 25%. Those experiencing migraine with aura have an almost twofold increased risk of cardiovascular disease. (41,42) Migraine with aura is also strongly associated with ischemic stroke. (108) Not surprisingly, migraineurs are more likely to report “cold extremities.” (111)

Diagnostics & Differential

Patients whose symptoms fit the broad definition of migraine rarely require imaging. (43) Plain film radiographs have little value in the diagnosis of migraine headache. When alternate pathology is suspected, MRI is the preferred neuroimaging choice over CT. (43) Suspicion of cerebral vascular pathology (aneurysm, vasculitis, arterial dissection) is better screened through magnetic resonance angiography (MRA). (44) The use of EEG lacks sensitivity and specificity for the diagnosis of migraine. (45)

The primary conditions to consider in the differential diagnosis of migraine headache are tension-type headache, TIA and stroke. Tension-type headaches are typically bilateral, non-pulsatile, and not aggravated by physical activity. Patients report that their symptoms are less intense and are generally not associated with nausea or vomiting. The symptoms of stroke or TIA generally develop more quickly, last longer (days to indefinitely), and do not occur in isolation. Other conditions to consider in the differential diagnosis of migraine headache include giant cell arteritis, cluster headaches, acute glaucoma, meningitis, neoplasm, and cerebrovascular bleed. (46)  


Migraine treatment is subdivided into “abortive” therapies that seek to stop or reverse the progression of an existing headache and “prophylactic” treatments, which seek to prevent or reduce the frequency of future attacks. Abortive treatments are most effective when given within the first minutes of an attack. (47) Abortive medications include analgesics, NSAIDs, selective serotonin receptor agonists, and ergot alkaloids. (48) Narcotics are commonly used for the emergency treatment of migraine, although evidence suggests they are ineffective and may lead to prolonged hospital stays. (82) Overuse of abortive medical therapy may generate a self-perpetuating, chronic “rebound” cycle of migraine. (50,51) For recurrent headaches, the American Headache Society discourages the use of over-the-counter pain medications or the prescription of opioids or butalbital medications. (43)

Prophylactic treatment is aimed at controlling migraine triggers. Several clinical trials and research studies suggest that spinal manipulation is an appropriate treatment for migraine headaches. (49,52-62,95) A Harvard study found that SMT reduced migraine days as well as pain intensity. (95) Another paper demonstrated a “significant reduction” of migraine intensity in almost half of those patients receiving spinal manipulation. Nearly ¼ of migraine patients reported greater than 90% fewer attacks. (55) Spinal manipulation has demonstrated similar effectiveness but longer lasting benefit with fewer side effects when compared to a well-known and efficacious medical treatment (amitriptyline). (55,57,58,61) A study to define adverse events following chiropractic spinal manipulation for migraines found that “adverse events were mild and transient, and severe or serious adverse events were not observed.” (89) Spinal manipulation is thought to inhibit pain through various mechanisms, including CNS activation, elevation of endorphin levels, disruption of pain-spasm-pain cycles, and reduction of mechanical triggers. (63-65)

Manual therapy, including soft tissue manipulation and massage therapy, has demonstrated success in the treatment of migraine headache. (66,67,90,101) Upper cervical hypertonicity or joint dysfunction is thought to be a trigger for headaches, including migraine. (65) Migraine patients harbor trigger points in the SCMupper trapezius, and/or splenius capitis that, when activated, can reproduce migraine headache. (86) Clinicians should pay particular attention to the suboccipital muscles, since the rectus capitis posterior minor shares a dense connective tissue bridge with the pain sensitive spinal dura at the level of the atlantooccipital junction. Soft tissue manipulation and myofascial release techniques are appropriate for the treatment of related cervical, interscapular, and shoulder girdle musculature. Dry needling may be helpful for managing migraine headaches. (106)

Clinicians should assess for and treat posture abnormalities, including weakness of the deep neck flexors and upper crossed syndrome. Acupuncture and biofeedback may be useful in the treatment of migraine. (51,68,69,79,83,100,107,109,119,120,122) Yoga may help migraine patients. (114) The FDA recently approved a transcranial magnetic stimulator (TMS) for the treatment of migraine headaches, and early studies have demonstrated improved outcomes from TMS over no treatment. (70,71)

The patient’s self-management should focus on trigger avoidance and stress management. (72) Mindfulness-based stress reduction is an effective treatment option for episodic migraine. (118) A headache diary is essential to help identify and eliminate triggers. (73) No specific diet has been shown to help migraine, but patients should be coached to identify and eliminate their unique food triggers. (22) Patients with medication triggers, including oral contraceptives and hormones, should consult with their medical providers about changing or discontinuing those drugs. (47) Aerobic exercise can provide a significant reduction in migraine frequency, intensity, and duration. (116) Exercising for 40 minutes, three times per week has shown similar benefit to a proven prophylactic medication. (84) Migraineurs, particularly those who are overweight, should be given dietary advice. (117) Migraineurs with aura should be counseled on the increased risk of stroke associated with smoking and oral contraceptive use. (8) Clinicians should encourage adequate hydration, as research has found a significant correlation between migraine and inadequate water intake. (115)

Magnesium supplementation (400-600mg/ day) has strong support for preventing and relieving migraines. (92) Vitamin D deficiency is associated with migraine attacks. (97,98) Vitamin D supplementation in a dose of 1000-4000 IU/d has been shown to reduce the frequency of migraine attacks. (98,104,105) Vitamin B6 supplementation (with or without concurrent B9 and B12) has demonstrated prophylactic benefit. (110) Limited data supports the use of various other supplements, including melatonin, Feverfew (125mg/ day), and riboflavin (400mg/ day) for the prevention of migraine in non-pregnant patients. (50,75-78,85,112)

Medications used for the prophylaxis of migraine include: beta-blockers, tricyclic antidepressants, and divalproex sodium or valproic acid. (50) Recently, Botox injections have been used with some success for the treatment of migraine. (91) Surgical deactivation of migraine trigger points is discouraged by the American Headache Society. (43)  


1. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24 Suppl 1:9-160

2. Silberstein SD, Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, Göbel H, Lainez MJ, Lance JW, Lipton RB. The International Classification of Headache Disorders, (ICHD-II)—-Revision of Criteria for 8.2 Medication-Overuse Headache. Cephalalgia. 2005 Jun;25(6):460-5. Link

3. Wolff HG. Headache and other head pain. InHeadache and other head pain 1948.

4. May A, Goadsby PJ. The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. Journal of Cerebral Blood Flow & Metabolism. 1999 Feb;19(2):115-27. Link

5. Dodick DW, Gargus JJ. Why migraines strike. Scientific American. 2008 Aug 1;299(2):56-63. Link

6. Waeber C, Moskowitz MA. Therapeutic implications of central and peripheral neurologic mechanisms in migraine. Neurology. 2003 Oct 28;61(8 suppl 4):S9-20. Link

7. Moskowitz MA. The visceral organ brain: implications for the pathophysiology of vascular head pain. Neurology. 1991 Feb 1;41(2 Part 1):182-.

8. Chawla J. Migraine Headache. Medscape. Accessed 2/1/14 from: Link

9. Welch KM. Contemporary concepts of migraine pathogenesis. Neurology. 2003 Oct 28;61(8 suppl 4):S2-8. Link

10. Sun-Edelstein C, Mauskop A. Role of magnesium in the pathogenesis and treatment of migraine. Expert review of neurotherapeutics. 2009 Mar 1;9(3):369-79. Link

11. Stovner LJ, Hagen K, Jensen R, Katsarava Z, Lipton RB, Scher AI, Steiner TJ, Zwart JA. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007 Mar;27(3):193-210. Link

12. Lipton RB, Scher AI, Kolodner K, Liberman J, Steiner TJ, Stewart WF. Migraine in the United States: epidemiology and patterns of health care use. Neurology. 2002 Mar 26;58(6):885-94. Link

13. Stewart WF, Linet MS, Celentano DD, Natta MV, Ziegler D. Age-and sex-specific incidence rates of migraine with and without visual aura. American journal of epidemiology. 1991 Nov 15;134(10):1111-20. Link

14. Burton WN, Landy SH, Downs KE, Runken MC. The impact of migraine and the effect of migraine treatment on workplace productivity in the United States and suggestions for future research. InMayo Clinic Proceedings 2009 May 1 (Vol. 84, No. 5, pp. 436-445). Elsevier. Link

15. Hsu LC, Wang SJ, Fuh JL. Prevalence and impact of migrainous vertigo in mid-life women: a community-based study. Cephalalgia. 2011 Jan;31(1):77-83. Link

16. Kors EE, Haan J, Ferrari MD. Genetics of primary headaches. Curr Opin Neurol. Jun 1999;12(3):249-54.

17. Cleveland Clinic. Diseases and Conditions- Migraine Headaches. Accessed 2/8/14 from: Link

18. Hamed SA. The vascular risk associations with migraine: relation to migraine susceptibility and progression. Atherosclerosis. 2009 Jul 1;205(1):15-22. Link

19. Bigal ME, Lipton RB. Excessive acute migraine medication use and migraine progression. Neurology. 2008 Nov 25;71(22):1821-8. Link

20. MacGregor EA. Menstrual migraine. Curr Opin Neurol. Jun 2008;21(3):309-15.

21. Allais G, Gabellari IC, De Lorenzo C, Mana O, Benedetto C. Oral contraceptives in migraine. Expert review of neurotherapeutics. 2009 Mar 1;9(3):381-93. Link

22. Wöber C, Brannath W, Schmidt K, Kapitan M, Rudel E, Wessely P, Wöber?Bingöl Ç, PAMINA Study Group. Prospective analysis of factors related to migraine attacks: the PAMINA study. Cephalalgia. 2007 Apr;27(4):304-14. Link

23. University of California-Berkeley, University Health Services. Migraine Triggers. Accessed 2/8/14 from: Link

26. Migraine with Aura. Accesssed 2/8/14 from: Link

28. Silberstein SD, Freitag FG. Preventative treatment of migraine. Neurology. 2003;60(7):S38-44.

30. Pryse-Phillips WE, Dodick DW, Edmeads JG, Gawel MJ, Nelson RF, Purdy RA, Robinson G, Stirling D, Worthington I. Guidelines for the diagnosis and management of migraine in clinical practice. Cmaj. 1997 May 1;156(9):1273-87. Link

31. Russell MB, Rasmussen BK, Fenger K, Olesen J. Migraine without aura and migraine with aura are distinct clinical entities: a study of four hundred and eighty-four male and female migraineurs from the general population. Cephalalgia. 1996 Jun;16(4):239-45. Link

32. Barbanti P, Fabbrini G, Pesare M, Cerbo R. Neurovascular symptoms during migraine attacks. Cephalalgia. 2001 May 1;21(4).

34. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(7):1-96.

36. Lipton RB, Dodick D, Sadovsky RE, Kolodner K, Endicott J, Hettiarachchi J, Harrison W. A self-administered screener for migraine in primary care: The ID Migraine™ validation study. Neurology. 2003 Aug 12;61(3):375-82. Link

37. Silberstein SD, Lipton RB, Dalessio DJ. Overview, diagnosis, and classification. In: Silberstein SD, Lipton RB, Dalessio DJ, eds. Wolff’s Headache And Other Head Pain. 7th ed. Oxford, England: Oxford University Press; 2001:20

38. Dodick DW. Adv Stud Med. 2003; 3 (6C): S550-S555

39. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(7):1-96.

41. Woodward M. Migraine and the risk of coronary heart disease and ischemic stroke in women. Womens Health (Lond Engl). Jan 2009;5(1):69-77.

42. Scher AI, Gudmundsson LS, Sigurdsson S, Ghambaryan A, Aspelund T, Eiriksdottir G, van Buchem MA, Gudnason V, Launer LJ. Migraine headache in middle age and late-life brain infarcts. Jama. 2009 Jun 24;301(24):2563-70. Link

43. Loder E, Weizenbaum E, Frishberg B, Silberstein S, American Headache Society Choosing Wisely Task Force. Choosing Wisely in Headache Medicine: The A merican Headache Society’s List of Five Things Physicians and Patients Should Question. Headache: The Journal of Head and Face Pain. 2013 Nov;53(10):1651-9. Link

44. Leclerc X, Gauvrit JY, Nicol L, Pruvo JP. Contrast-enhanced MR angiography of the craniocervical vessels: a review. Neuroradiology. 1999 Dec 1;41(12):867-74. Link

45. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: The electroencephalogram in the evaluation of headache (summary statement). Neurology. 1995;45:1411-1413

46. Gilmore, B; Michael, M (2011-02-01). “Treatment of acute migraine headache”. American family physician 83 (3): 271–80.

47. Kelman L. Women’s issues of migraine in tertiary care. Headache: The Journal of Head and Face Pain. 2004 Jan;44(1):2-7. Link

48. Matchar DB, Young WB, Rosenberg JH, Pietrzak MP, Silberstein SD, Lipton RB, Ramadan NM. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management of acute attacks. Neurology. 2000 Apr;54. Link

49. Astin JA, Ernst E. The effectiveness of spinal manipulation for the treatment of headache disorders: a systematic review of randomized clinical trials. Cephalalgia. 2002 Oct;22(8):617-23. Link

50. Parsekyan D. Migraine prophylaxis in adult patients. Western Journal of Medicine. 2000 Nov;173(5):341. Link

51. Tfelt-Hansen P. Prophylactic pharmacotherapy of migraine: some practical guidelines. Neurologic clinics. 1997 Feb 1;15(1):153-65. Link

52. Brønfort G, Nilsson N, Haas M, Evans RL, Goldsmith CH, Assendelft WJ, Bouter LM. Non-invasive physical treatments for chronic/recurrent headache. Cochrane Database of Systematic Reviews. 2004(3). Link

53. Parker GB, Pryor DS, Tupling H. Why does migraine improve during a clinical trial? Further results from a trial of cervical manipulation for migraine. Australian and New Zealand journal of medicine. 1980 Apr;10(2):192-8. Link

54. Tuchin PJ, Pollard H, Bonello R. A randomized controlled trial of chiropractic spinal manipulative therapy for migraine. Journal of manipulative and physiological therapeutics. 2000 Feb 1;23(2):91-5. Link

55. Nelson CF, Bronfort G, Evans R, Boline P, Goldsmith C, Anderson AV. The efficacy of spinal manipulation, amitriptyline and the combination of both therapies for the prophylaxis of migraine headache. Journal of manipulative and physiological therapeutics. 1998 Oct;21(8):511-9. Link

56. Harris SP. Chiropractic management of a patient with migraine headache. Journal of chiropractic medicine. 2005;4(1):25. Link

57. Biondi DM. Physical treatments for headache: a structured review. Headache: The Journal of Head and Face Pain. 2005 Jun;45(6):738-46. Link

58. Bronfort G, Assendelft WJ, Evans R, Haas M, Bouter L. Efficacy of spinal manipulation for chronic headache: a systematic review. Journal of manipulative and physiological therapeutics. 2001 Sep 1;24(7):457-66. Link

59. Noudeh YJ, Vatankhah N, Baradaran HR. Reduction of current migraine headache pain following neck massage and spinal manipulation. International journal of therapeutic massage & bodywork. 2012;5(1):5. Link

60. Stodolny J, Chmielewski H. Manual therapy in the treatment of patients with cervical migraine. Manual Med. 1989;4:49-51.

61. Boline PD, Kassak K, Bronfort G, Nelson C, Anderson AV. Spinal manipulation vs. amitriptyline for the treatment of chronic tension-type headaches: a randomized clinical trial. Journal of Manipulative and Physiological Therapeutics. 1995;18(3):148-54. Link

62. Bryans R, Descarreaux M, Duranleau M, Marcoux H, Potter B, Ruegg R, Shaw L, Watkin R, White E. Evidence-based guidelines for the chiropractic treatment of adults with headache. Journal of manipulative and physiological therapeutics. 2011 Jun 1;34(5):274-89. Link

63. Vicenzino B, Collins D, Benson H, Wright A. An investigation of the interrelationship between manipulative therapy-induced hypoalgesia and sympathoexcitation. Journal of manipulative and physiological therapeutics. 1998 Sep;21(7):448-53. Link

ddd64. Maigne JY, Vautravers P. Mechanism of action of spinal manipulative therapy. Joint bone spine. 2003 Sep 1;70(5):336-41. Link

65. Gay RE, Nelson CF. Clinical efficacy of chiropractic treatment. In: Wainapel SF, Fast A, editors. Alternative Medicine and Rehabilitation: A Guide for Practitioners. New York: Demos Medical Publishing; 2003. pp. 67–71.

66. Lawler SP, Cameron LD. A randomized, controlled trial of massage therapy as a treatment for migraine. Annals of Behavioral Medicine. 2006 Aug 1;32(1):50-9. Link

67. Jay WM, Lipton SA. Prevention of Classic Migraine Headache by Digital Massage of the Superficial Temporal Arteries during Visual Aura. Journal of Neuro-Ophthalmology. 1986 Dec 1;6(4):259. Link

68. Linde K, Allais G, Brinkhaus B, Manheimer E, Vickers A, White AR: Acupuncture for migraine prophylaxis. Cochrane Database Syst Rev 2009, CD001218.

69. Nestoriuc Y, Martin A, Rief W, Andrasik F. Biofeedback treatment for headache disorders: a comprehensive efficacy review. Applied psychophysiology and biofeedback. 2008 Sep 1;33(3):125-40. Link

70. US Food and Drug Administration. FDA allows marketing of first device to relieve migraine headache pain [press release]. December 13, 2013. Available at

71. Jeffrey S. FDA approves first device to treat migraine pain. Medscape Medical News. 2013.

72. Network SI. Diagnosis and management of headache in adults. Edinburgh: NHS Quality Improvement Scotland. 2008.

73. Noble SL, Moore KL. Drug treatment of migraine: Part II. Preventive therapy. American family physician. 1997 Dec;56(9):2279-86. Link

75. Ramadan NM, Silberstein SD, Freitag FG, Gilbert TT, Frishberg BM, for the US Headache Consortium. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management for prevention of migraine. Am Acad Neurol Web site

76. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high?dose riboflavin in migraine prophylaxis A randomized controlled trial. Neurology. 1998 Feb 1;50(2):466-70. Link

77. Peikert A, Wilimzig C, Köhne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia. 1996 Jun;16(4):257-63. Link

78. Pfaffenrath V, Wessely P, Meyer C, Isler HR, Evers S, Grotemeyer KH, Taneri Z, Soyka D, Göbel H, Fischer M. Magnesium in the prophylaxis of migraine?a double?blind, placebo?controlled study. Cephalalgia. 1996 Oct;16(6):436-40. Link

79. Evans RM. Managing migraine today (II): pharmacologic and nonpharmacologic treatment [JAMA Migraine Information Center Web site]. October 1998.

80. Cutrer FM, Charles A. The neurogenic basis of migraine. Headache: The Journal of Head and Face Pain. 2008 Oct;48(9):1411-4. Link

81. Bille BO. Migraine in childhood and its prognosis. Cephalalgia. 1981 Jun;1(2):71-5. Link

82. Sahai-Srivastava S, Desai P, Zheng L. Analysis of headache management in a busy emergency room in the United States. Headache: The Journal of Head and Face Pain. 2008 Jun;48(6):931-8. Link

83. Yang CP, Chang MH, Liu PE, Li TC, Hsieh CL, Hwang KL, Chang HH. Acupuncture versus topiramate in chronic migraine prophylaxis: a randomized clinical trial. Cephalalgia. 2011 Nov;31(15):1510-21. Link

84. Varkey E, Cider Å, Carlsson J, Linde M. Exercise as migraine prophylaxis: a randomized study using relaxation and topiramate as controls. Cephalalgia. 2011 Oct;31(14):1428-38. Link

85. Chiu HY, Yeh TH, Huang YC, Chen PY. Effects of intravenous and oral magnesium on reducing migraine: a meta-analysis of randomized controlled trials. Pain Physician. 2016 Jan 1;19(1):E97-112. Link

86. Florencio LL, Ferracini GN, Chaves TC, Palacios-Ceña M, Ordás-Bandera C, Speciali JG, Falla D, Grossi DB, Fernández-de-las-Peñas C. Active trigger points in the cervical musculature determine the altered activation of superficial neck and extensor muscles in women with migraine. The Clinical journal of pain. 2017 Mar 1;33(3):238-45. Link

87. Carvalho GF, Florencio LL, Pinheiro CF, Dach F, Bigal ME, Bevilaqua-Grossi D. Functional balance deterioration on daily activities in patients with migraine: A controlled study. American journal of physical medicine & rehabilitation. 2018 Feb 1;97(2):90-5. Link

88. Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: figures and trends from government health studies. Headache: The Journal of Head and Face Pain. 2018 Apr;58(4):496-505. Link

89. Chaibi A, Benth JŠ, Tuchin PJ, Russell MB. Adverse events in a chiropractic spinal manipulative therapy single-blinded, placebo, randomized controlled trial for migraineurs. Musculoskeletal Science and Practice. 2017 Jun 1;29:66-71. Link

90. Espí-López GV, Ruescas-Nicolau MA, Nova-Redondo C, Benítez-Martínez JC, Dugailly PM, Falla D. Effect of soft tissue techniques on headache impact, disability, and quality of life in migraine sufferers: a pilot study. The journal of alternative and complementary medicine. 2018 Nov 1;24(11):1099-107. Link

91. Bruloy E, Sinna R, Grolleau JL, Bout-Roumazeilles A, Berard E, Chaput B. Botulinum toxin versus placebo: A meta-analysis of prophylactic treatment for migraine. Plastic and reconstructive surgery. 2019 Jan 1;143(1):239-50. Link

92. Veronese N, Demurtas J, Pesolillo G, Celotto S, Barnini T, Calusi G, Caruso MG, Notarnicola M, Reddavide R, Stubbs B, Solmi M. Magnesium and health outcomes: an umbrella review of systematic reviews and meta-analyses of observational and intervention studies. European journal of nutrition. 2019 Jan 25:1-0. Link

93. Oliveira-Souza AI, Florencio LL, Carvalho GF, Fernández-De-Las-Peñas C, Dach F, Bevilaqua-Grossi D. Reduced flexion rotation test in women with chronic and episodic migraine. Brazilian journal of physical therapy. 2019 Jan 16. Link

94. Ismail OM, Poole ZB, Bierly SL, Van Buren ED, Lin FC, Meyer JJ, Davis RM. Association Between Dry Eye Disease and Migraine Headaches in a Large Population-Based Study. JAMA ophthalmology. 2019 May 1;137(5):532-6. Link

95. Rist PM, Hernandez A, Bernstein C, Kowalski M, Osypiuk K, Vining R, Long CR, Goertz C, Song R, Wayne PM. The Impact of Spinal Manipulation on Migraine Pain and Disability: A Systematic Review and Meta-Analysis. Headache: The Journal of Head and Face Pain. 2019 Apr;59(4):532-42. Link

96. van der Meer HA, Visscher CM, Vredeveld T, Nijhuis van der Sanden MW, HH Engelbert R, Speksnijder CM. The diagnostic accuracy of headache measurement instruments: A systematic review and meta-analysis focusing on headaches associated with musculoskeletal symptoms. Cephalalgia. 2019 Sep;39(10):1313-32. Link

97. Patel U, Kodumuri N, Malik P, Kapoor A, Malhi P, Patel K, Saiyed S, Lavado L, Kapoor V. Hypocalcemia and Vitamin D Deficiency amongst Migraine Patients: A Nationwide Retrospective Study. Medicina. 2019 Aug;55(8):407. Link

98. Ghorbani Z, Togha M, Rafiee P, Ahmadi ZS, Magham RR, Haghighi S, Jahromi SR, Mahmoudi M. Vitamin D in migraine headache: a comprehensive review on literature. Neurological Sciences. 2019 Aug 3:1-9. Link

99. Li W, Bertisch SM, Mostofsky E, Buettner C, Mittleman MA. Weather, ambient air pollution, and risk of migraine headache onset among patients with migraine. Environment international. 2019 Nov 1;132:105100. Link

100. Chen YY, Li J, Chen M, Yue L, She TW, Zheng H. Acupuncture versus propranolol in migraine prophylaxis: an indirect treatment comparison meta-analysis. Journal of neurology. 2019 Aug 21:1-2. Link

101. Maistrello LF, Rafanelli M, Turolla A. Manual Therapy and Quality of Life in People with Headache: Systematic Review and Meta-analysis of Randomized Controlled Trials. Current pain and headache reports. 2019 Oct 1;23(10):78. Link

102. Nyberg J, Gustavsson S, Linde M, Åberg ND, Rohmann JL, Åberg M, Kurth T, Waern M, Kuhn GH. Cardiovascular fitness and risk of migraine: a large, prospective population-based study of Swedish young adult men. BMJ open. 2019 Aug 1;9(8):e029147. Link

103. Terrin A, Mainardi F, Lisotto C, Mampreso E, Fuccaro M, Maggioni F, Zanchin G. A prospective study on osmophobia in migraine versus tension-type headache in a large series of attacks. Cephalalgia. 2019 Sep 19:0333102419877661. Link

104. Nowaczewska M, Wiciski M, Osi?ski S, Kamierczak H. The Role of Vitamin D in Primary Headache–from Potential Mechanism to Treatment. Nutrients. 2020 Jan;12(1):243.

105. Ghorbani Z, Togha M, Rafiee P, Ahmadi ZS, Magham RR, Djalali M, Shahemi S, Martami F, Zareei M, Jahromi SR, Ariyanfar S. Vitamin D3 might improve headache characteristics and protect against inflammation in migraine: a randomized clinical trial. Neurological Sciences. 2020 Jan 2:1-0. Link

106. Vázquez-Justes D, Yarzábal-Rodríguez R, Doménech-García V, Herrero P, Bellosta-López P. Analysis of the effectiveness of the dry puncture technique in headaches: systematic review. Neurology. 2020 Jan 13. Link

107. Xu S, Yu L, Luo X, Wang M, Chen G, Zhang Q, Liu W, Zhou Z, Song J, Jing H, Huang G. Manual acupuncture versus sham acupuncture and usual care for prophylaxis of episodic migraine without aura: multicentre, randomised clinical trial. BMJ. 2020 Mar 25;368. Link

108. Øie LR, Kurth T, Gulati S, Dodick DW. Migraine and risk of stroke. Journal of Neurology, Neurosurgery & Psychiatry. 2020 Mar 26. Link

109. Xu S, Yu L, Luo X, Wang M, Chen G, Zhang Q, Liu W, Zhou Z, Song J, Jing H, Huang G. Manual acupuncture versus sham acupuncture and usual care for prophylaxis of episodic migraine without aura: multicentre, randomised clinical trial. BMJ. 2020 Mar 25;368. Link

110. Liampas I, Siokas V, Aloizou A, Tsouris Z, Metaxia D, Aslanidou P, Brotis A, Dardiotis E. Pyridoxine, folate and cobalamin for migraine: A Systematic Review. Acta Neurologica Scandinavica. 2020 Apr 12. Link

111. Linstra KM, Perenboom MJ, van Zwet EW, van Welie FC, Fronczek R, Tannemaat MR, Wermer MJ, Maassenvandenbrink A, Terwindt GM. Cold extremities in migraine: a marker for vascular dysfunction in women. European Journal of Neurology. 2020 Apr 30. Link

112. Liampas I, Siokas V, Brotis A, Vikelis M, Dardiotis E. Endogenous Melatonin Levels and Therapeutic Use of Exogenous Melatonin in Migraine: Systematic Review and Meta-Analysis. Headache: The Journal of Head and Face Pain. 2020 Apr 30. Link

113. Natbony LR, Zhang N. Acupuncture for Migraine: a Review of the Data and Clinical Insights. Current Pain and Headache Reports. 2020 May 29;24(7):32-. Link

114. Kumar A, Bhatia R, Sharma G, Dhanlika D, Vishnubhatla S, Tripathi M, Dash D, Singh R, Srivastava MP. Effect of Yoga as add on Therapy in Migraine (CONTAIN): A Randomized controlled study (1570). Link

115. Khorsha F, Mirzababaei A, Togha M, Mirzaei K. Association of drinking water and migraine headache severity. Journal of Clinical Neuroscience. 2020 May 20. Link

116. Barber M, Pace A. Exercise and Migraine Prevention: a Review of the Literature. Current Pain and Headache Reports. 2020 Aug;24(8):1-7. Link

117. Altamura C, Cecchi G, Bravo M, Brunelli N, Laudisio A, Caprio PD, Botti G, Paolucci M, Khazrai YM, Vernieri F. The Healthy Eating Plate advice for Migraine prevention: an interventional study. Nutrients. 2020 Jun;12(6):1579. Link

118. Seminowicz DA, Burrowes SA, Kearson A, Zhang J, Krimmel SR, Samawi L, Furman AJ, Keaser ML, Gould NF, Magyari T, White L. Enhanced mindfulness-based stress reduction in episodic migraine: a randomized clinical trial with magnetic resonance imaging outcomes. Pain. 2020 Aug 1;161(8):1837-46. Link

119. Kristoffersen ES, Børte S, Hagen K, Zwart JA, Winsvold BS. Migraine, obesity and body fat distribution–a population-based study. The Journal of Headache and Pain. 2020 Dec;21(1):1-8. Link

120. Fan SQ, Jin S, Tang TC, Chen M, Zheng H. Efficacy of acupuncture for migraine prophylaxis: a trial sequential meta-analysis. Journal of Neurology. 2020 Aug 24:1-0. Link

121. Simi S, Rabi-Žiki T, Villar JR, Calvo-Rolle JL, Simi D, Simi SD. Impact of Individual Headache Types on the Work and Work Efficiency of Headache Sufferers. International Journal of Environmental Research and Public Health. 2020 Jan;17(18):6918. Link

122. Patel M, Urits I, Kaye AD, Viswanath O. The Role of Acupuncture in the treatment of chronic pain. Best Practice & Research Clinical Anaesthesiology. 2020 Aug 8. Link

About Author

Tim Bertelsman, DC, DACO

Dr. Bertelsman graduated from Logan College of Chiropractic with honors in 1991 and has been running a large successful multi disciplinary practice in Belleville, IL for over 20 years. He is an expert on establishing relationships within the medical community.He has lectured nationally for many years on clinical and business topics and has been published extensively. He has served in various leadership positions within the Illinois Chiropractic Society and currently serves as President of the executive board. Dr. Bertelsman is a Co-founder of ChiroUp.


Corporate Club


Article Categories